<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The number of <z:e sem="disease" ids="C0850624" disease_type="Disease or Syndrome" abbrv="">cardiovascular risk factors</z:e> significantly influences age adjusted cardiovascular <z:hpo ids='HP_0011420'>death</z:hpo> rates according to the data of the MRFIT Trial </plain></SENT>
<SENT sid="1" pm="."><plain>Up to 60% of patients with Type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> have concomitant <z:hpo ids='HP_0000822'>hypertension</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>In the <z:chebi fb="106" ids="33811">HOT</z:chebi> (<z:hpo ids='HP_0000822'>Hypertension</z:hpo> Optimal Treatment) Study lowering of blood pressure was particularly beneficial in the subgroup of <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo>: there was a 51% reduction in major cardiovascular events in target group&lt;or=80 mmHg, compared with target group&lt;or=90 mmHg (p=0.005) </plain></SENT>
<SENT sid="3" pm="."><plain>Analysis of the diabetic patient group in the CAPPP (The CAPtopril Prevention Project) showed that <z:chebi fb="0" ids="3380">captopril</z:chebi> was superior for preventing cardiovascular events in hypertensive patients with <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="4" pm="."><plain>In the diabetic cohort of the LIFE Study <z:chebi fb="0" ids="6541">losartan</z:chebi> was more effective than athenolol in reducing <z:e sem="disease" ids="C1301700" disease_type="Disease or Syndrome" abbrv="">cardiovascular morbidity</z:e> and mortality as well as mortality from <z:hpo ids='HP_0000001'>all</z:hpo> causes in patients with <z:hpo ids='HP_0000822'>hypertension</z:hpo>, <z:mp ids='MP_0002055'>diabetes</z:mp> and <z:hpo ids='HP_0001712'>left ventricular hypertrophy</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>In the Heart Protection Study 5963 people with <z:mp ids='MP_0002055'>diabetes</z:mp> were studied </plain></SENT>
<SENT sid="6" pm="."><plain>For the first occurrence of any major vascular events among diabetic participants, there was a 22% reduction in the event rate <z:chebi fb="0" ids="9150">simvastatin</z:chebi>-allocated versus placebo allocated patients (p&lt;0.0001) </plain></SENT>
<SENT sid="7" pm="."><plain>DAIS (<z:mp ids='MP_0002055'>Diabetes</z:mp> <z:hpo ids='HP_0002621'>Atherosclerosis</z:hpo> Intervention Study) data suggest that treatment with <z:chebi fb="0" ids="5001">fenofibrate</z:chebi> reduces the angiographic progression of <z:hpo ids='HP_0001677'>coronary artery disease</z:hpo> in patients with Type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="8" pm="."><plain>According to results on multifactorial intervention in patients with Type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> (the STENO-2 study) the overall cardiovascular risk reduction was 53% </plain></SENT>
<SENT sid="9" pm="."><plain>In conclusion, management of <z:e sem="disease" ids="C0850624" disease_type="Disease or Syndrome" abbrv="">cardiovascular risk factors</z:e> should be considered as the cornerstone of <z:mp ids='MP_0002055'>diabetes</z:mp> care </plain></SENT>
</text></document>